Freestyle Libre, that is the name of the new wearable glucose monitor created by Abbott. They shared the results of their clinical trial at this year’s annual meeting of the American Diabetes Association. Some of the results include that wearers of the device spent 38% less time in hypoglycemia compared to patients that still need to do a blood prick test to monitor their blood glucose levels.
One of the major advantages of the monitor is that patients who wore it during the first two weeks of the trial, tested themselves on average 15 times a day, compared to the 3 times a day if they have to do a blood prick test.
The Libre is a small round device which is worn on the back of the upper arm. It is scanned with a reader to obtain the blood glucose levels. A blood prick is only needed in certain instances, for example if the system detects that hypoglycemia or impeding hypoglycemia is imminent.
According to the trial’s chief investigator, Dr. Jan Bolinder of the Karolinska Institutet in Stockholm; “Hypoglycemia is the main barrier to attaining optimum glucose control in persons with insulin-treated diabetes. Moreover, hypoglycemic events can not only lead to adverse clinical outcomes including cardiovascular events and death, but they can also incur significant emergency healthcare costs. This clinical trial has proven that patients will test more often when they have an easier and more convenient way to do so utilizing a device like FreeStyle Libre, leading them to ultimately being healthier, which is our goal for our patients.”
The trial was carried out in Austria, Germany, Netherlands, Spain and Sweden. The device received a CE mark in 2014. It is available in Australia, Brazil as well as 11 European countries. A professional-use version, named FreeStyle Libre Pro, is available in India and South Africa.
For more information on this, please go to: http://www.massdevice.com/abbott-touts-clinical-trial-wearable-glucose-monitor-ada/